Shareholders Approve 10.4M Share Increase for Incentive Plan; Executive Pay Barely Passes

summarizeSummary

Novavax shareholders approved a significant increase of 10.4 million shares for its stock incentive plan, potentially diluting existing shareholders, while also narrowly approving executive compensation amidst ongoing activist pressure.

check_boxKey Events · Financing and Capital Events · NVAX

• Significant Share Authorization Approved

  Shareholders approved an amendment to the 2015 Stock Incentive Plan, authorizing an additional 10.4 million shares for future equity awards, representing approximately 6.3% potential dilution based on current outstanding shares.

• Executive Compensation Barely Passes

  The advisory vote on executive compensation was approved by a narrow margin (50.6% For), reflecting notable shareholder dissent, particularly in the context of ongoing activist pressure.

• Director Nominees Elected Amidst Activism

  All three Class I director nominees were elected to the board for three-year terms, following a period of public campaigning by activist investor Shah Capital against the company's leadership.

• Employee Stock Purchase Plan Approved

  The 2013 Employee Stock Purchase Plan was also amended and restated, further increasing the pool of shares available for issuance.

auto_awesomeAnalysis · NVAX · Life Sciences

The approval of an additional 10.4 million shares for Novavax's stock incentive plan, representing over 6% potential dilution, provides the company with a substantial pool for future equity compensation. This comes after activist investor Shah Capital has been campaigning for leadership changes and share buybacks. The narrow approval of executive compensation, with only 50.6% of votes cast in favor, further highlights significant shareholder dissent regarding corporate governance and compensation practices. This authorization for future share issuance could weigh on the stock, especially given the company's recent net loss in Q1 2026.